FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections

Influenza virus (IV) infections pose a burden on global public health with significant morbidity and mortality. The limited range of currently licensed IV antiviral drugs is susceptible to the rapid rise of resistant viruses. In contrast, FDA-approved kinase inhibitors can be repurposed as fast-trac...

Descripción completa

Detalles Bibliográficos
Autores principales: Meineke, Robert, Stelz, Sonja, Busch, Maximilian, Werlein, Christopher, Kühnel, Mark, Jonigk, Danny, Rimmelzwaan, Guus F., Elbahesh, Husni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504178/
https://www.ncbi.nlm.nih.gov/pubmed/36146864
http://dx.doi.org/10.3390/v14092058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504178/
https://www.ncbi.nlm.nih.gov/pubmed/36146864
http://dx.doi.org/10.3390/v14092058

Ejemplares similares